In BRAF-mutant melanomas, therapy resistance to vemurafenib is supported by the Sterol Regulatory Element-Binding Protein (SREBP1) activation [56] and the upregulation of the S1 P-dependent signaling pathway [37,40,51,52,57]. Here, BRAF is linked to melanoma.